Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?

Paar V, Wernly B, Zhou Z, Motloch LJ, Hoppe UC, Egle A, Lichtenauer M

J Thromb Thrombolysis - (-) - [2020-07-06; online 2020-07-06]

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been linked to a higher risk of mortality compared to influenza, which is mainly due to severe secondary diseases, such as acute respiratory distress syndrome (ARDS). In turn, ARDS is characterized by an acute inflammation and an excessive activity of the coagulation cascade, rising the vulnerability for venous thromboembolic events. In order to investigate the relation of inflammation and the influence of coagulation factors on their release, human peripheral mononuclear blood cells (PBMCs) were treated with autologous serum, heparinized plasma and different doses of fibrin. Thereafter, the concentration of pro-inflammatory cytokines and chemokines in the secretome of PBMCs was measured by enzyme-linked immunosorbent assay. Our analyses revealed autologous serum to significantly increase the secretion of cytokines and chemokines after 24 h of incubation time. Furthermore, the addition of fibrin markedly increased the secretion of cytokines and chemokines by PBMCs in a dose-dependent manner. Consequently, in accordance with previous studies, our study outlines that anti-coagulation may constitute a promising tool for the treatment of SARS-CoV-2, reducing both, the cytokine storm, as well as the risk for thrombotic complications.

Category: Biochemistry

Type: Journal article

PubMed 32632558

DOI 10.1007/s11239-020-02212-6

Crossref 10.1007/s11239-020-02212-6

pii: 10.1007/s11239-020-02212-6
pmc: PMC7338133

Publications 7.1.2